Breast cancer is cancer that develops from breast tissue. Risk factors for developing breast cancer include being female, obesity , a lack of physical exercise, alcoholism , hormone replacement therapy during menopause , ionizing radiation , an early age at first menstruation , having children late in life or not at all, older age, having a prior history of breast cancer, and a family history of breast cancer. The balance of benefits versus harms of breast cancer screening is controversial. A Cochrane review found that it was unclear if mammographic screening does more harm than good, in that a large proportion of women who test positive turn out not to have the disease. Outcomes for breast cancer vary depending on the cancer type, the extent of disease , and the person's age.
10 Things Women With Breast Implants Should Know About Cancer Screening
Radiotherapy for primary breast cancer | Breast Cancer Now
This extensive surgery is rarely done now. The surgeon removes the entire breast, axillary underarm lymph nodes, and the pectoral chest wall muscles under the breast. This surgery was once very common, but less extensive surgery such as the modified radical mastectomy has been found to be just as effective and with fewer side effects. This operation may still be done for large tumors that are growing into the pectoral muscles.
Cancer patients, their caregivers, and others need to take precautions to lower their risk of getting COVID, which is caused by a new type of coronavirus. Learn you can do to help protect yourself and others. Jill Chang says she always knew she might get cancer some day.
Mammography is the most widely used screening modality for the detection of breast cancer. There is evidence that it decreases breast cancer mortality in women aged 50 to 69 years and that it is associated with harms, including the detection of clinically insignificant cancers that pose no threat to life overdiagnosis. The benefit of mammography for women aged 40 to 49 years is uncertain. Some of these studies have suggested a shift in late-stage disease; however, there is still insufficient evidence to conclude a mortality benefit.